Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference17 articles.
1. Fokotomi T, Akashi-Tanaka S: Prognostic and predictive factors in the adjuvant treatment of breast cancer. Breast Cancer 2002, 9:95–99. A thorough discussion of prognostic and predictive factors for early stage breast cancer is provided. Factors which have not been validated prospectively are highlighted.
2. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998, 352:930–942. The report represents a detailed analysis of the last published meta-analysis of randomized adjuvant chemotherapy trials for early stage breast cancer. The impact of treatment duration, anthracyclines, hormone receptor status, and the addition of tamoxifen to chemotherapy are detailed.
3. Henderson IC, Berry D, Demetri G, et al.: Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer [abstract]. Proc Am Soc Clin Oncol 1998, 17:101a.
4. The National Institutes of Health Consensus Development Conference: adjuvant therapy for breast cancer. Bethesda, Maryland, USA. J Natl Cancer Inst Monogr 2001, 30:1–152. The monograph reflects the content of lectures delivered by participants in the National Institutes of Health Consensus Development Conference. The monograph serves as a primer on all aspects of adjuvant therapy of breast cancer. In addition, perspective is given to areas where there are gaps in knowledge or data.
5. Thomas E, Buzdar A, Theriault R, et al.: Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of prospective randomized clinical trial [abstract]. Proc Am Soc Clin Oncol 2000, 19:74a.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献